摘要肝癌手术切除后复发是严重制约肝癌患者远期疗效的瓶颈.微血管侵犯(MVI)是肝癌最具特征性的病理生物学行为,也是临床突破肝癌术后复发瓶颈的一个重要着力点.我国新的MVI病理诊断标准和分级方案已经写入国家《原发性肝癌诊疗规范》.这既指明了临床实施肝癌术后抗复发治疗的重要病理学指征,也是临床制定肝癌术后抗复发治疗方案的重要病理学依据,需要我们熟知善用.今后应注重开展多学科联合研究,力争在MVI的发生机制、移行路径、分布特点、精准识别和有效治疗等方面取得实质性进展,以进一步提高肝癌患者的远期疗效.

abstractsRecurrence after surgical resection is a bottleneck that severely restricts the long-term efficacy of patients with liver cancer, mainly referring to hepatocellular carcinoma and intrahepatic cholangio-carcinoma. As the most representative pathobiological feature of liver cancer, microvascular invasion ( MVI) should be taken as an important focus to break through the bottleneck of postoperative recurrence. The new pathological diagnostic criteria and classification scheme of MVI has been written into the current"Guidelines for Diagnosis and Treatment of Primary Liver Cancer" of China. It is not only an important pathological indi-cation for the clinical implementation of anti-recurrence therapy after operation, but also an key pathological basis for the clinical formulation of postoperative anti-recurrent therapy. Therefore, we intend to investigate how to make better use of it. From now on, multidisciplinary research should be strengthened in order to make real progress in the occurrence mechanism, migration pathway, distribution pattern, accurate identifi-cation and effective treatment of MVI in order to further improve the long-term efficacy of patients with liver cancer.